Ibio Inc (IBIO) Stock Price, Quote & News

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies agai...

Industry: Biotechnology

Sector: Healthcare

Phone: 979 446 0027

Website: ibioinc.com

Address:

11750 Sorrento Valley Road, Suite 200, San Diego, United States

IBIO_KEVINTL Oct. 24 at 11:41 PM

$IBIO more catalyst!!!

0 · Reply

isaacwilliams33 Oct. 24 at 10:19 PM

$TOVX $AREB $RBNE VOLATILE. Looking closely at $ALTS $IBIO get at good price

0 · Reply

LowFloatScanner_ Oct. 24 at 8:37 PM

What is happening to ticker CMCT right now?! CMCT is breaking out like crazy.. only 700k float Are they pumping up ticker CMCT for 300% today!? Looks like all eyes are moving to CMCT now.. Watching: $CREV $IBIO $PLUG $BLNK longs

0 · Reply

BuyBigly Oct. 24 at 8:33 PM

$IBIO Probably a Democrat

0 · Reply

Rustie Oct. 24 at 8:05 PM

$IBIO Have a great weekend everyone !!$$$

0 · Reply

dcpanda Oct. 24 at 8:00 PM

$IBIO 6 more days! 🍻

1 · Reply

Azad1993 Oct. 24 at 4:21 PM

$IBIO Why is it not going up, from $2 yesterday down to this, I am really confused about the stock market.

2 · Reply

theflynews Oct. 24 at 4:19 PM

Biotech Alert: Searches spiking for these stocks today - $IBIO - https://thefly.com/permalinks/entry.php/IBIOid4220809?1761322703C38

0 · Reply

Zackpedia Oct. 24 at 3:43 PM

$IBIO You could’ve sold above 1.48 when I alerted and bought back at 1.14 today if you wanted, hit Follow and subscribe to get my alerts on time and make money

0 · Reply

trading_signal Oct. 24 at 3:43 PM

🌿 $IBIO Stair-step move higher with a healthy pullback. Buyers stepped in near prior breakout zone. Support: 1.268 Resistance: 1.28 → 1.296 📈 Above 1.296 could send this toward 1.35+. Below 1.268 would weaken structure.

0 · Reply

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 21, 2025, 7:00 AM EDT - 4 days ago

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Sep 5, 2025, 7:30 AM EDT - 7 weeks ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Aug 25, 2025, 7:00 AM EDT - 2 months ago

iBio Announces Closing of $50 Million Public Offering

Aug 19, 2025, 8:01 AM EDT - 2 months ago

iBio Announces Pricing of $50 Million Public Offering

Aug 18, 2025, 4:01 PM EDT - 2 months ago

iBio Announces Proposed Public Offering

Jun 24, 2025, 7:00 AM EDT - 4 months ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Jun 23, 2025, 4:15 PM EDT - 4 months ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Jun 16, 2025, 7:00 AM EDT - 4 months ago

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

May 5, 2025, 8:00 AM EDT - 6 months ago

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 2, 2025, 8:00 AM EDT - 6 months ago

iBio Reports Fiscal Third Quarter 2025 Financial Results

Apr 29, 2025, 1:43 PM EDT - 6 months ago

iBio Raises $6.2 Million Through Warrant Inducement Transaction

Apr 22, 2025, 8:00 AM EDT - 6 months ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 7, 2025, 7:00 AM EDT - 7 months ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Feb 19, 2025, 4:05 PM EST - 8 months ago

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 10, 2025, 4:05 PM EST - 9 months ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

Jan 2, 2025, 7:00 AM EST - 10 months ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Nov 12, 2024, 4:05 PM EST - 1 year ago

iBio Reports Fiscal First Quarter 2025 Financial Results

Sep 20, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 3, 2024, 7:00 AM EDT - 1 year ago

iBio to Participate in Upcoming Investor Conferences

Aug 12, 2024, 4:30 PM EDT - 1 year ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Jun 3, 2024, 7:00 AM EDT - 1 year ago

iBio Closes Sale of Manufacturing Facility in Texas

May 13, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Mar 27, 2024, 2:43 PM EDT - 1 year ago

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 7:00 AM EDT - 1 year ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 26, 2024, 7:35 PM EDT - 1 year ago

iBio Announces $15.0 Million Private Placement

Feb 26, 2024, 7:45 AM EST - 1 year ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Jan 16, 2024, 8:15 AM EST - 1 year ago

iBio Announces Participation in 23rd Annual PepTalk Conference

Jan 16, 2024, 6:50 AM EST - 1 year ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI VYNE

Dec 26, 2023, 7:15 AM EST - 1 year ago

iBio Amends and Extends Maturity of Credit Agreement

Dec 5, 2023, 8:00 AM EST - 2 years ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Nov 27, 2023, 5:20 PM EST - 2 years ago

iBio Announces Reverse Stock Split

Nov 1, 2023, 8:24 AM EDT - 2 years ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Oct 2, 2023, 6:45 AM EDT - 2 years ago

iBio Explains Recent Filing of Registration Statement

Sep 27, 2023, 4:19 PM EDT - 2 years ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 21, 2023, 4:05 PM EDT - 2 years ago

iBio Announces Amendment to Credit Agreement with Woodforest

Aug 14, 2023, 4:15 PM EDT - 2 years ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Jun 27, 2023, 8:00 AM EDT - 2 years ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 12, 2023, 4:15 PM EDT - 2 years ago

iBio Forges Research Collaboration with the National Institutes of Health

May 9, 2023, 4:30 PM EDT - 2 years ago

iBio to Participate in the JMP Securities Life Sciences Conference

Apr 4, 2023, 4:05 PM EDT - 2 years ago

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

Mar 31, 2023, 8:10 AM EDT - 2 years ago

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Feb 16, 2023, 4:48 PM EST - 2 years ago

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

Dec 9, 2022, 4:05 PM EST - 3 years ago

iBio Announces Closing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 11:27 PM EST - 3 years ago

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 4:01 PM EST - 3 years ago

iBio Announces Proposed Underwritten Public Offering

Dec 5, 2022, 8:00 AM EST - 3 years ago

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

Dec 2, 2022, 4:30 PM EST - 3 years ago

iBio Announces CEO Departure

Sep 27, 2022, 10:33 PM EDT - 3 years ago

iBio, Inc. (IBIO) Q4 2022 Results - Earnings Call Transcript

Sep 27, 2022, 4:10 PM EDT - 3 years ago

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

IBIO_KEVINTL Oct. 24 at 11:41 PM

$IBIO more catalyst!!!

0 · Reply

isaacwilliams33 Oct. 24 at 10:19 PM

$TOVX $AREB $RBNE VOLATILE. Looking closely at $ALTS $IBIO get at good price

0 · Reply

LowFloatScanner_ Oct. 24 at 8:37 PM

0 · Reply

BuyBigly Oct. 24 at 8:33 PM

$IBIO Probably a Democrat

0 · Reply

Rustie Oct. 24 at 8:05 PM

$IBIO Have a great weekend everyone !!$$$

0 · Reply

dcpanda Oct. 24 at 8:00 PM

$IBIO 6 more days! 🍻

1 · Reply

Azad1993 Oct. 24 at 4:21 PM

$IBIO Why is it not going up, from $2 yesterday down to this, I am really confused about the stock market.

2 · Reply

theflynews Oct. 24 at 4:19 PM

Biotech Alert: Searches spiking for these stocks today - $IBIO - https://thefly.com/permalinks/entry.php/IBIOid4220809?1761322703C38

0 · Reply

Zackpedia Oct. 24 at 3:43 PM

$IBIO You could’ve sold above 1.48 when I alerted and bought back at 1.14 today if you wanted, hit Follow and subscribe to get my alerts on time and make money

0 · Reply

trading_signal Oct. 24 at 3:43 PM

0 · Reply

drenicatrade Oct. 24 at 2:58 PM

$IBIO no shares available 😢

0 · Reply

dcpanda Oct. 24 at 2:52 PM

$IBIO shirts running out of gas to push this below 1. Nasdaq com0liance is inevitable. Reversal coming with continued upside 🍻

0 · Reply

IBIO_KEVINTL Oct. 24 at 2:27 PM

$IBIO Shorts trying like hell but can’t get it under a buck

0 · Reply

The_Fifteen_Percent_Guy Oct. 24 at 1:48 PM

$IBIO No price action showing floor confirmation yet, BUT 30min RSI has just hit previous bottom. Indicating, this is the likely loading-zone. >>>

0 · Reply

The_Fifteen_Percent_Guy Oct. 24 at 12:47 PM

$IBIO 𝗪𝗮𝘀 𝗮 𝗯𝗮𝗻𝗴𝗲𝗿 𝗳𝗼𝗿 𝗰𝗹𝗼𝘀𝗲 𝘁𝗼 𝟳𝟬% 𝗮𝘁 𝟮 𝗺𝗮𝗿𝗸 𝘆𝗲𝘀𝘁𝗲𝗿𝗱𝗮𝘆! ✏️ If you missed the first round > almost certain the MM will start to set a new floor today to form a base for the next leg up to begin from. ⮕ We can then expect multi-day volume surges going into the Nov 4-7 data catalysts as well as likely compliance PRs that correspond with a spike in volume & stock price. > In order to spark retail buying interest targeting/chasing a move to the psychological 7$ March peak ⮕ MM/Dealer/Placement agent will likely use this momentum to offload AUG 21 offering shares between the $3- $5.5 zone. 📈

0 · Reply

LJB411 Oct. 24 at 12:23 PM

$BLMZ Heating up. Also holding $DVLT $STAI $IBIO $RPGL

0 · Reply

Cash_is__King Oct. 24 at 10:44 AM

$IBIO whats everyone trading right now

0 · Reply

trading_momentum_x Oct. 24 at 9:58 AM

$IBIO nice base breakout into a gap up . 5/100dema cross on great volume but major major resistance in this area producing a bearish piercing pattern potentially here. Would wait and see if tomorrows close can surpass today’s and continue closing above the 5dEMA

0 · Reply

trading_signal Oct. 24 at 9:17 AM

$IBIO Measuring the recent impulse of the local price structure gives us a road map for what to expect next. Price has moved from a .382 of local structure down to a 1.414 0 a 1.5 deviation total. finding support at the 1.414 near $1.21 can send us up to target $1.55 on a retrace Target 1.55 Support near 1.07 if we get drop further

0 · Reply

IBIO_KEVINTL Oct. 24 at 8:17 AM

$IBIO Let’s go today!

0 · Reply

milk25 Oct. 24 at 6:41 AM

$IBIO 1.40 overnight

0 · Reply

IBIO_KEVINTL Oct. 24 at 2:36 AM

$IBIO The flippers and panic sellers are mainly gone. So it’s not a pump and dump Or at least it dumped already It leveled off With average down and People that sold and now are Buying back So I see Upside from here This is a good price

1 · Reply

Market Cap	25.72M
Revenue (ttm)	400,000.00
Net Income (ttm)	-18.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,595.00%
Debt to Equity Ratio	0.06

Volume	4,253,800
Avg Vol	3,592,440
Day's Range	N/A - N/A
Shares Out	20.26M
Stochastic %K	45%
Beta	0.89
Analysts	Strong Sell
Price Target	$3.40